Literature DB >> 29967967

Perspectives on Genetic Testing and Return of Results from the First Cohort of Presymptomatically Tested Individuals At Risk of Huntington Disease.

K M Stuttgen1,2, J M Bollinger1, R L Dvoskin1, A McCague1,2, B Shpritz3, J Brandt3,4, Debra J H Mathews5.   

Abstract

This qualitative study gathered opinions about genetic testing from people who received presymptomatic testing for Huntington's disease (HD) 20-30 years ago and have lived with the implications of that testing for decades. During the last section of a semi-structured interview, participants were asked open-ended questions about their opinions on the importance of autonomy in the decision to be tested for HD, whether a formal HD testing protocol is necessary, whether physician ordering for HD is acceptable without a formal protocol, whether online direct-to-consumer (DTC) genetic testing for HD is acceptable, and whether incidental/secondary findings should be returned in the context of whole exome/genome sequencing. Most-but not all-participants were in favor of an individual's right to decide whether and when to pursue HD testing, use of a formal HD testing protocol, and returning medically actionable secondary findings. However, the majority of participants were opposed not only to physician ordering and DTC HD testing in the absence of a formal protocol but also to returning a secondary finding of an expanded HD allele. This study presents the opinions of a unique and extremely well-informed cohort on issues that need to be taken into careful consideration by genetic counselors and other medical professionals who are developing genetic testing protocols, making decisions about the availability of genetic tests, and making decisions about whether and how to return incidental findings.

Entities:  

Keywords:  Direct-to-consumer testing; Genetic testing; Huntington’s disease; Incidental findings; Qualitative research

Mesh:

Year:  2018        PMID: 29967967      PMCID: PMC6212306          DOI: 10.1007/s10897-018-0274-0

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  28 in total

1.  Predictive testing for Huntington's disease: a universal model?

Authors:  Michael R Hayden
Journal:  Lancet Neurol       Date:  2003-03       Impact factor: 44.182

2.  Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test.

Authors:  Reinier Timman; Raymund Roos; Anneke Maat-Kievit; Aad Tibben
Journal:  Health Psychol       Date:  2004-03       Impact factor: 4.267

3.  Delivery of Internet-based cancer genetic counselling services to patients' homes: a feasibility study.

Authors:  Neal J Meropol; Mary B Daly; Hetal S Vig; Frank J Manion; Sharon L Manne; Carla Mazar; Camara Murphy; Nicholas Solarino; Vadim Zubarev
Journal:  J Telemed Telecare       Date:  2010-11-19       Impact factor: 6.184

4.  Psychiatric implications of presymptomatic testing for Huntington's disease.

Authors:  Seymour Kessler
Journal:  Am J Orthopsychiatry       Date:  1987-04

5.  Predictive testing for Huntington's disease with use of a linked DNA marker.

Authors:  G J Meissen; R H Myers; C A Mastromauro; W J Koroshetz; K W Klinger; L A Farrer; P A Watkins; J F Gusella; E D Bird; J B Martin
Journal:  N Engl J Med       Date:  1988-03-03       Impact factor: 91.245

6.  Presymptomatic diagnosis of delayed-onset disease with linked DNA markers. The experience in Huntington's disease.

Authors:  J Brandt; K A Quaid; S E Folstein; P Garber; N E Maestri; M H Abbott; P R Slavney; M L Franz; L Kasch; H H Kazazian
Journal:  JAMA       Date:  1989-06-02       Impact factor: 56.272

7.  Improved predictive testing for Huntington disease by using three linked DNA markers.

Authors:  M R Hayden; C Robbins; D Allard; J Haines; S Fox; J Wasmuth; M Fahy; M Bloch
Journal:  Am J Hum Genet       Date:  1988-11       Impact factor: 11.025

8.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.

Authors:  Sarah S Kalia; Kathy Adelman; Sherri J Bale; Wendy K Chung; Christine Eng; James P Evans; Gail E Herman; Sophia B Hufnagel; Teri E Klein; Bruce R Korf; Kent D McKelvey; Kelly E Ormond; C Sue Richards; Christopher N Vlangos; Michael Watson; Christa L Martin; David T Miller
Journal:  Genet Med       Date:  2016-11-17       Impact factor: 8.822

9.  Video-confidence: a qualitative exploration of videoconferencing for psychiatric emergencies.

Authors:  Marianne Vibeke Trondsen; Stein Roald Bolle; Geir Øyvind Stensland; Aksel Tjora
Journal:  BMC Health Serv Res       Date:  2014-10-31       Impact factor: 2.655

10.  ACMG statement on direct-to-consumer genetic testing.

Authors: 
Journal:  Genet Med       Date:  2004 Jan-Feb       Impact factor: 8.822

View more
  1 in total

Review 1.  Genetic counseling and testing practices for late-onset neurodegenerative disease: a systematic review.

Authors:  Ashley Crook; Chris Jacobs; Toby Newton-John; Rosie O'Shea; Alison McEwen
Journal:  J Neurol       Date:  2021-03-01       Impact factor: 6.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.